ImmunityBio Plummets 21% After FDA Warning Over Cancer Drug Claims

ImmunityBio Inc. ($IBRX) shares suffered a severe rout this week after federal regulators issued a damning warning letter regarding misleading promotional claims made by the company's executive leadership about its cancer treatment Anktiva. The stock collapsed more than 21% on March 24, 2026, obliterating nearly $2 billion in market capitalization in a single trading session. The dramatic selloff has triggered a securities class action investigation by law firm Hagens Berman, which alleges that company executives, including executive chairman Dr. Patrick Soon-Shiong, knowingly misrepresented the drug's approved uses to investors and the public.

The FDA's Regulatory Rebuke

The Food and Drug Administration determined that ImmunityBio engaged in deceptive promotional practices through materials that falsely suggested Anktiva could treat cancers broadly across the market. In reality, the medication has received approval exclusively for non-muscle invasive bladder cancer (NMIBC), a far narrower indication than the company's marketing suggested.

Key issues identified by regulators include:

• Misleading efficacy claims implying broad-based cancer treatment capabilities
• Promotional materials overstating the drug's approved uses beyond bladder cancer
• Executive statements attributed to Dr. Soon-Shiong that characterized the drug's potential in ways not supported by clinical data or regulatory approval
• Investor communications that may have inflated market expectations regarding the drug's commercial scope

The warning letter represents a significant regulatory enforcement action, signaling the FDA's concern that ImmunityBio crossed the line from legitimate promotion into territory that could mislead both healthcare providers and patients about what Anktiva can actually treat. Such warning letters carry substantial weight in the biotech sector, as they can trigger immediate market reactions and frequently precede more serious enforcement actions.

Market Collapse and Legal Fallout

The magnitude of ImmunityBio's one-day collapse reflects both the market's sensitivity to regulatory actions in the life sciences sector and investor concerns about potential leadership culpability. The $2 billion market capitalization loss underscores how quickly investor confidence can evaporate when regulatory credibility comes into question.

Hagens Berman's investigation into the matter suggests that securities litigation could represent an additional headwind for the company. Class action lawsuits following significant stock declines typically allege that company insiders made materially false or misleading statements, either through direct communications or by failing to disclose known risks to investors. The timing of the investigation—launched immediately following the FDA warning—indicates legal counsel believes there may be credible grounds for investor claims.

Investor losses in such scenarios can be substantial, particularly for those who purchased shares based on management's characterizations of Anktiva's market potential. The investigation's 4-day deadline mentioned in the original reporting likely refers to a window for investors to register their interest in joining the class action before formal deadlines pass.

Market Context and Sector Implications

This episode arrives at a particularly fraught time for the biotechnology sector, where regulatory credibility and executive transparency have become paramount concerns for institutional investors. The broader biotech industry has faced heightened scrutiny in recent years regarding promotional practices, especially as companies bring novel therapeutics to market amid intense competitive pressures.

ImmunityBio's troubles carry implications beyond the company itself:

• Regulatory vigilance: The FDA's enforcement action signals active monitoring of company promotional practices, potentially affecting how other biotech firms describe their products to investors
• Sector sentiment: Biotechnology stocks, which depend heavily on investor confidence in pipeline potential, often trade at valuations reflecting management credibility. A major breach like this can create broader caution across the sector
• Institutional trust: Life sciences companies depend on relationships with investors, healthcare providers, and patients. Regulatory warnings damage all three constituencies simultaneously
• Competitive landscape: Competitors to ImmunityBio may benefit from market share gains if Anktiva loses prescriber confidence or if the company faces operational disruptions from the investigation

The company's focus on cancer immunotherapy, once a promising area with strong investor enthusiasm, now faces additional headwinds from this regulatory and legal situation. Other immunotherapy developers are likely watching this case closely, as it demonstrates the risks of aggressive marketing claims.

Investor Implications and Forward Outlook

For shareholders, the implications of this regulatory action extend beyond the immediate stock price decline. Several critical questions loom:

Near-term considerations:

• Will the FDA impose additional restrictions on Anktiva marketing or distribution?
• How extensive is the potential securities litigation exposure, and what could settlement costs reach?
• Will institutional investors reduce positions in ImmunityBio, creating continued selling pressure?
• How will Dr. Patrick Soon-Shiong's leadership role be affected by the regulatory findings?

Longer-term challenges:

• Anktiva sales momentum may suffer if healthcare providers and patients lose confidence in the drug's positioning
• The company's ability to attract investment capital for future research and development could be compromised
• Executive compensation arrangements and board oversight practices may face investor scrutiny
• The company's pipeline of other oncology candidates may face heightened due diligence from the investment community

Biotech investors should recognize that regulatory warnings, particularly those involving promotional practices attributed to company leadership, often foreshadow more substantial challenges. The interconnection between regulatory credibility, stock performance, and shareholder liability creates a cascading effect that can persist well beyond the initial announcement.

ImmunityBio's situation underscores a fundamental principle in healthcare investing: companies in highly regulated industries cannot afford to let promotional enthusiasm outpace regulatory approval scope. The cost of such missteps—measured in shareholder value destruction, legal liability, and damaged market credibility—can be substantial and long-lasting. Investors should closely monitor the company's regulatory filings, the progression of the Hagens Berman investigation, and any statements from company leadership regarding the FDA warning for additional clarity on the company's path forward. The coming weeks will likely prove decisive in determining whether this represents a localized management issue or a broader erosion of investor confidence that could impact the company's long-term viability.